The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trialA. Huijbers, Wilma E. Mesker, Rob A.�E.�M. Tollenaar et al.|Annals of Oncology|2012Cited by 348
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-AnalysisDan Rosmarin, Ian D. Tomlinson, Angela Jones et al.|Journal of Clinical Oncology|2014Cited by 261